Try our beta test site

Stopping Heavy Periods Project (SHiPP)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Women and Infants Hospital of Rhode Island
Information provided by (Responsible Party):
Kristen Matteson , M.D., Women and Infants Hospital of Rhode Island Identifier:
First received: November 27, 2013
Last updated: October 4, 2016
Last verified: October 2016
This study is a randomized clinical trial comparing the levonorgestrel intrauterine system (LNG-IUS) to combined oral contraceptives (COCs) for treatment of heavy menstrual bleeding. This study is designed to be conducted within the context of a patient's standard/usual/typical care from their primary gynecologic care provider. We hypothesize that, compared to COCs, the LNG-IUS will be more effective at improving bleeding-related quality of life and will be associated with fewer treatment failures and greater cost-effectiveness at one year. To test these hypotheses, we plan to enroll 59 women from several sites who present for gynecologic care and self-report heavy menstrual bleeding into a RCT comparing LNG-IUS to COCs. The eligible study population includes women with heavy menstrual bleeding secondary to ovulatory disorders (AUB-O) or endometrial hemostatic disorders (AUB-E). Women meeting study eligibility will be randomized to receive LNG-IUS or COCs. Main study outcomes will be obtained at 6 weeks, 3 months, 6 months, and 1 year.

Condition Intervention
Abnormal Uterine Bleeding
Abnormal Uterine Bleeding, Ovulatory Dysfunction
Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Device: Levonorgestrel intrauterine system
Drug: Combined oral contraceptives

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Levonorgestrel Intrauterine System Versus Oral Contraceptives for Heavy Menses

Resource links provided by NLM:

Further study details as provided by Women and Infants Hospital of Rhode Island:

Primary Outcome Measures:
  • Menstrual Bleeding Questionnaire [ Time Frame: Completed 5 times over a one year time period ]
    We will measure bleeding-specific quality of life using the Menstrual Bleeding Questionnaire (MBQ), a validated tool to assess bleeding-related quality of life, which is the most important outcome for patients and for clinicians treating this symptom. We will measure MBQ score at randomization, and at 6 weeks, 3 month, 6 months, and 12 months post-randomization for both groups

Secondary Outcome Measures:
  • Treatment Failure [ Time Frame: Information collected at four time points during a one year period post randomization ]
    The goal of treating heavy menstrual bleeding is to utilize a treatment option that improves patient quality of life and avoids surgical intervention. We will look at treatment failure two different ways. We will determine the overall proportion of participants who discontinued their assigned treatment (opted for no treatment or chose a different treatment option, including surgery) and subset that opted for surgical intervention (endometrial ablation or hysterectomy) during the study period. This information will be recorded by the primary gynecologic provider (physical examination and physician form), by participants (interval health history form), and by the research team (medical record review).

Estimated Enrollment: 59
Study Start Date: February 2013
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Levonorgestrel intrauterine system
levonorgestrel intrauterine system with 52 mg of levonorgestrel, levonorgestrel is released at a rate of approximately 20 μg/day. Inserted once, duration 5 years.
Device: Levonorgestrel intrauterine system
Other Name: Mirena
Active Comparator: Combined oral contraceptives
A combined ethinyl estradiol (ee) and progestin oral contraceptive pill chosen by the participants' primary gynecologic care provider. Monophasic with 30 or 35 mcg ee administered according to pill pack instructions (21 days active pills, 7 placebo pills)
Drug: Combined oral contraceptives
Other Names:
  • Any combined oral contraceptive of the provider's choice so long
  • as it contains 30-35 mg of ethinyl estradiol.


Ages Eligible for Study:   18 Years to 51 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Self-reported heavy menstrual bleeding
  • Age 18-51 years
  • Etiology of heavy menstrual bleeding from either ovulatory disorders (AUB-O) or endometrial hemostatic disorders (AUB-E)

Exclusion Criteria:

  • Plan pregnancy in the next year
  • Menopausal
  • Currently has a copper IUD in place
  • History of ablation or hysterectomy or have any contraindications to COCs or LNG-IUS
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02002260

Contact: Mindy Marshall, MS 401-274-1122 ext 48561

United States, Rhode Island
Gynecologic practices affiliated with Women and Infants Hospital Recruiting
Providence, Rhode Island, United States, 02905
Contact: Tracey Ferreira   
Principal Investigator: Kristen A. Matteson, MD, MPH         
Sub-Investigator: Melissa A. Clark, PhD         
Sponsors and Collaborators
Women and Infants Hospital of Rhode Island
Principal Investigator: Kristen A Matteson, M.D., M.P.H. Women and Infants Hospital
  More Information

Responsible Party: Kristen Matteson , M.D., Associate Professor of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island Identifier: NCT02002260     History of Changes
Other Study ID Numbers: R01HD074751 ( US NIH Grant/Contract Award Number )
Study First Received: November 27, 2013
Last Updated: October 4, 2016

Additional relevant MeSH terms:
Uterine Hemorrhage
Pathologic Processes
Uterine Diseases
Genital Diseases, Female
Contraceptives, Oral, Combined
Ethinyl Estradiol
Contraceptive Agents
Contraceptives, Oral
Contraceptive Agents, Female
Reproductive Control Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Contraceptives, Oral, Synthetic processed this record on March 29, 2017